Related Experiment Video
Updated: Mar 22, 2026
06:15
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
52.6K
Fulminant liver failure in a neonate
Naomi E Clarke1, Damien Gilby1, Helen Savoia2
1Department of Neonatal Services, Royal Women's Hospital, Melbourne, Victoria, Australia.
Journal of Paediatrics and Child Health
|April 29, 2016
Summary
Neonatal acute liver disease, though rare, has diverse causes. This case highlights gestational alloimmune liver disease as a cause of neonatal liver failure, emphasizing its confirmation post-mortem and implications for future pregnancies.
Area of Science:
- Neonatology
- Hepatology
- Immunology
Background:
- Neonatal acute liver disease is uncommon, with varied origins like infections, metabolic issues, and immune-related conditions.
- Gestational alloimmune liver disease (GALD) is a rare but severe cause of neonatal liver failure.
Observation:
- A preterm, growth-restricted infant presented with severe neonatal liver failure.
- Extensive investigations were performed to determine the underlying cause of liver failure.
Findings:
- The infant was clinically diagnosed with gestational alloimmune liver disease.
- This diagnosis was definitively confirmed through post-mortem examination.
- The case underscores the diagnostic challenges and fatal outcome of GALD in neonates.
Implications:
- Management strategies for neonatal liver failure and GALD require careful consideration.
- Maternal management in subsequent pregnancies is crucial for preventing recurrence of GALD.
- This case contributes to understanding GALD and improving outcomes for affected families.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
315
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
315
01:20Inborn Errors of Metabolism
996
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
996